Home / News / Meridian Medical Technologies, LLC, and the European Commission’s DG HERA sign agreement for 13 countries from the EEA to purchase Tecovirimat SIGA

Meridian Medical Technologies, LLC, and the European Commission’s DG HERA sign agreement for 13 countries from the EEA to purchase Tecovirimat SIGA

October 23, 2023

ST. LOUIS, Mo. and WOODBURY, Minn.; Oct. 23, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority). As part of a promotional licensing agreement, Meridian is a global commercialization partner for SIGA Technologies, Inc. (NASDAQ: SIGA), which is the marketing authorization holder and manufacturer of Tecovirimat SIGA. Under the JPA, 13 participating countries from the European Economic Area (EEA) (Contracting Parties) can now efficiently purchase Tecovirimat SIGA, which has been approved by the European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications. This agreement will result in country-level procurement of oral Tecovirimat SIGA and serve as a template for future procurement opportunities.

“Time is of the essence during medical emergencies, as we saw in 2022 when EU member states required emergency shipments of Tecovirimat SIGA to treat patients infected with mpox,” said Meridian Commercial Head – Injectables & Health Security, Tom Handel. “This joint procurement framework contract, a significant milestone for both Meridian and HERA, reduces the time and effort required to put individual contracts in place with each member state from months to days. There are now multiple paths in Europe for streamlined procurement, allowing member state agencies to get much needed medical countermeasures into the hands of those in need.”

About Meridian Medical Technologies, LLC
Meridian Medical Technologies, LLC, a division of Kindeva Drug Delivery, is a global health security leader that provides medical countermeasures to agencies around the world. The company has been putting emergency care treatment options into the hands of military and civilian defenders for more than 60 years, including the United States Department of Defense, emergency medical services, homeland security, and more than 30 nations around the world, to help defend against critical, time-sensitive, life-or-death situations.

About Health Emergency Preparedness and Response Authority (HERA)
HERA is a key pillar of the European Health Union and a fundamental asset to strengthen the EU’s health emergency response and preparedness. HERA was established in September 2021 to replace ad hoc solutions to pandemic management and response with a permanent structure with adequate tools and resources to plan the EU action in case of health emergencies. One of the key goals of HERA is to ensure the development, manufacturing, procurement, and equitable distribution of key medical countermeasures.

Share article:

Related news

Explore more of our latest news and announcements, where the demands of today meet the possibilities of tomorrow.

Kindeva Drug Delivery awarded up to $129 million to supply DuoDote® autoinjectors to the Strategic National Stockpile

ST. LOUIS, Mo. and WOODBURY, Minn: 16th Jan 2025 (Business Wire) – Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies, LLC, secured a contract valued at up to $129 million to supply DuoDote®, a chemical nerve agent antidote autoinjector, to the Strategic National Stockpile (SNS), managed by the Administration for Strategic Preparedness and […]

Learn More

Kindeva Drug Delivery and Emervax partner to bring game changing vaccine administration to patients

Woodbury, Minnesota and Houston, Texas – JAN 09, 2025:  Kindeva Drug Delivery, a global CDMO and drug delivery expert, and Emervax, a developer of a proprietary circular RNA-based vaccine platform (emxRNATM), today announced an exclusive partnership to co-develop a game-changing solution for the administration of vaccines targeting a variety of emerging viruses. Kindeva has granted […]

Learn More

Kindeva Global Health Security donates ATNAA to Ukraine through the European Commission’s rescEU and Governmental Strategic Reserves Agency (RARS)

WOODBURY, Minn. and ST. LOUIS, Mo.; May 29, 2024 (Business Wire) – Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection […]

Learn More

Kindeva Drug Delivery and Syntegon install first Versynta microBatch in North America

Waiblingen, Germany/Minneapolis, USA, April 9, 2024. Syntegon today announced the sale of its newly developed Versynta microBatch production cell to its first U.S. customer. Kindeva Drug Delivery will use Versynta microBatch to further expand its suite of aseptic fill-finish contract development and manufacturing (CDMO) capabilities meeting the latest global pharmaceutical regulations and trends. Kindeva is […]

Learn More

Kindeva Drug Delivery acquires Summit Biosciences, a specialized Nasal Drug Development and Manufacturing organization

WOODBURY, Minn., ST. LOUIS, Mo., LEXINGTON, Ky.; Jan. 18, 2024 (Business Wire) Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. Established in 2009, Summit has an extensive track […]

Learn More

Nutriband signs Commercial Development and Clinical Supply Agreement with Kindeva Drug Delivery for Aversa™ Fentanyl, an abuse deterrent fentanyl patch

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) […]

Learn More

Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) announce collaboration for Low GWP Propellant Conversion

WOODBURY, Minn. and St. LOUIS, Mo. and BOSTON; Dec. 5, 2023 – Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and […]

Learn More

Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, awarded contract to supply DuoDote®

ST. LOUIS, Mo. and WOODBURY, Minn.; Nov. 14, 2023 (Business Wire) – Meridian Medical Technologies, LLC (Meridian), a division of Kindeva Drug Delivery (Kindeva), has been awarded a $9.9M contract to supply DuoDote® to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services. Meridian is […]

Learn More

Viatris announces launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first FDA-approved generic version of Symbicort® for people with asthma and chronic obstructive pulmonary disease, in partnership with Kindeva

Launch demonstrates companies’ commitment to bringing complex generic medicines to the market to help increase patient access PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca’s Symbicort® with an Abbreviated […]

Learn More

Manufacturing more tomorrows

Partner with us and benefit from a team with technical expertise and a passion for purpose. As a true partner, strategically minded and dedicated to your lasting legacy, we provide customized solutions tailored to your precise requirements. From development to commercial manufacturing and beyond, our CDMO solutions are designed to help your product progress with purpose.